YIH
RLMD icon

Y-Intercept (HK)’s Relmada Therapeutics RLMD Stock Holding History

Y-Intercept (HK)’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-24,016
Closed -$112K – 1842
2024
Q1 		$112K Buy
+24,016
New +$116K 0.01% 1268
2023
Q3 		– Sell
-42,574
Closed -$105K – 1508
2023
Q2 		$105K Buy
+42,574
New +$118K 0.01% 1088

Other funds holding RLMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Y-Intercept (HK)'s RLMD Position: Q2 2024 in Review

Y-Intercept (HK) sold out of Relmada Therapeutics (RLMD) in Q2 2024, closing a stake of 24,016 shares — an estimated $112K sold.

Y-Intercept (HK) first reported a position in RLMD in Q2 2023 and held it in 2 quarters. The position peaked at $112K in Q1 2024. 79 funds tracked by Wall St. Rank hold RLMD as of Q2 2024.

  • Y-Intercept (HK) reported no remaining Relmada Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Y-Intercept (HK) sold 24,016 Relmada Therapeutics shares in Q2 2024, an estimated $112K.
  • Y-Intercept (HK) first reported a position in Relmada Therapeutics in Q2 2023 and held it in 2 quarters.
  • Y-Intercept (HK)'s Relmada Therapeutics position peaked at $112K in Q1 2024.
  • 79 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2024.

Based on Y-Intercept (HK)'s 13F filing for Q2 2024, filed 14 Aug 2024.